Search Results

You are looking at 241 - 250 of 1,168 items for :

  • Refine by Access: All x
Clear All
Full access

Yamini V. Ananth and Karisa Schreck

-based database using the REDCap tool. We analyzed data from 29 adults with primary brain tumors containing the BRAF V600E mutation, recording gender, age at diagnosis, tumor pathology, molecular tumor information, dates of surgeries, time to progression

Full access

Corbin D. Jacobs, Daniel J. Rocke, Russel R. Kahmke, Hannah Williamson, Gita Suneja, and Yvonne M. Mowery

diagnosed with invasive nonmetastatic ARSCC between 2010–2014 were identified. Exclusion criteria included prior malignancy, no/unknown surgery, unknown receipt of RT, RT dose <50 Gy or >80 Gy, RT fractions >68, T1–2N0 disease without identifiable NCCN

Full access

Giuseppe Curigliano

in all geo-cultural groups are particularly traumatized by the overt physical changes from breast cancer treatments. The stigmata of breast surgery and of treatment-related side effects such as hair loss and fatigue confirm to women the reality of

Full access

S. Machele Donat

Skinner DG Stein JP . Surgery and adjunctive chemotherapy for invasive bladder cancer . Surg Oncol 2002 ; 11 : 55 – 63 . 27 Nielsen ME Palapattu GS Karakiewicz PI . A delay in radical cystectomy of > 3 months is not associated with a worse

Full access

Jenna F. Borkenhagen, Daniel Eastwood, Deepak Kilari, William A. See, Jonathan D. Van Wickle, Colleen A. Lawton, and William A. Hall

,294,126 incident cases in the prostate PUF for 2004 through 2010. Of these, the subset of men with high-risk clinical T2N0M0 prostate cancer treated with curative-intent external-beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) ± surgery was

Full access

Seyed M. Qaderi, Paul W. Dickman, Johannes H.W. de Wilt, and Rob H.A. Verhoeven

with pathologic stage I–III colon or rectal cancer diagnosed and endoscopically or surgically treated between January 1995 and December 2016 in the Netherlands were included (N=178,384). Patients treated without surgery were excluded because resection

Full access

Yoshikuni Kawaguchi, Scott Kopetz, Heather A. Lillemoe, Hyunsoo Hwang, Xuemei Wang, Ching-Wei D. Tzeng, Yun Shin Chun, Thomas A. Aloia, and Jean-Nicolas Vauthey

CLM resection is to detect recurrence early, when both the patient and the disease recurrence are treatable. Repeat surgery is effective for recurrence after CLM resection. Reported 5-year overall survival (OS) rates in patients who undergo resection

Full access

Siyang Leng, Yizhen Chen, Wei-Yann Tsai, Divaya Bhutani, Grace C. Hillyer, Emerson Lim, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Suzanne Lentzsch, and Alfred I. Neugut

-related event (SRE). 4 , 5 Considerable evidence from randomized controlled trials supports the use of bisphosphonates. Pamidronate and zoledronic acid have been shown to significantly reduce SREs (defined as pathologic fracture, radiation to bone, surgery on

Full access

Timothy Paul Hanna, Geoffrey Paul Delaney, and Michael Bernard Barton

absolute proportional benefit (LC or OS) of RT alone over no treatment for radical RT indications. For adjuvant indications, RT benefit was the benefit of RT over surgery alone. For radical indications, the survival benefit was estimated to be equal to the

Full access

Timothy J. Wilt and Philipp Dahm

the United Kingdom–based ProtecT screening trial are expected soon and will be informative. 16 Recent treatment trials for localized disease demonstrate that reductions as a result of surgery compared with observation in prostate cancer or all